{
    "clinical_study": {
        "@rank": "127778", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "matching placebo (infusion bag) to VAY736, a single dose administered intravenously over 2 hours."
            }, 
            {
                "arm_group_label": "VAY736 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion of VAY736 at Dose Level 1, a single dose administered intravenously for 2 hours"
            }, 
            {
                "arm_group_label": "VAY736 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion of VAY736 at Dose Level 2, a single dose administered intravenously over 2 hours. Dose level 2 will be initiated following a safety review of patients receiving Dose Level 1 or placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety, tolerability and efficacy of a single intravneous infusion of\n      VAY736, compared to placebo, in pemphigus vulgaris patients."
        }, 
        "brief_title": "Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Pemphigus Vulgaris", 
        "condition_browse": {
            "mesh_term": "Pemphigus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients 20 to 70 years of age\n\n          -  Confirmed diagnosis of pemphigus vulgaris\n\n          -  Presence of mild to moderate pemphigus vulgaris\n\n          -  Patients must weight between 40 kg and 150 kg inclusive\n\n          -  on a stable dose of oral corticosteriod therapy (with or without azathioprine or\n             mycophenolate)\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Women of child-bearing potential unless they are using a highly effective method of\n             birth control during dosing and for 4 months following study treatment\n\n          -  Recent previous treatment with photo therapy, biological therapy, steroids,\n             immunosuppresive agents (unless washout period applied)\n\n          -  Active or recent history of clinically significant infection\n\n          -  use of rituximab within 1 year Other protocol-defined inclusion/exclusion criteria\n             may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930175", 
            "org_study_id": "CVAY736X2203"
        }, 
        "intervention": [
            {
                "arm_group_label": "VAY736 Dose 1", 
                "description": "VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner.", 
                "intervention_name": "VAY736", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo to VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner. All patients that receive placebo will be offered open-label VAY736.", 
                "intervention_name": "Placebo to VAY736", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "VAY736 Dose 2", 
                "description": "VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner, following a safety review.", 
                "intervention_name": "VAY736", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pemphigus vulgaris", 
            "pemphigus", 
            "blistering disease"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242-1091"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27516"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1431"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79104"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany", 
                        "zip": "35039"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel-Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 9RT"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Bulgaria", 
                "Germany", 
                "Israel", 
                "Taiwan", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Paul-Ehrlich-Institut", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Austria: Agency for Health and Food Safety", 
                "Taiwan: Center for Drug Evaluation"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The effect of VAY736 on clinical disease activity will be measured by the change in Pemphigus Disease Area Index (PDAI) between baseline and week 12. PDAI is an assessment of skin and mucosal disease activity by the Investigator. The score incorporates the number and size of lesions across multiple skin locations and the mucous membranes.", 
            "measure": "Efficacy of a single intravenous dose of VAY736 in reducing the clinical disease activity in pemphigus vulgaris patinets.", 
            "safety_issue": "No", 
            "time_frame": "baseline, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to an average of 12 months"
            }, 
            {
                "description": "The effect of VAY736 on the ABSIS score will be compared betwen baseline and Week 12. ABSIS is a quality and quantity-based score of skin and oral mucosal lesions, combining the extent of the affected body surface area, the quality of the lesion and the extent of oral mucosal involvement, including food-related pain and discomfort.", 
                "measure": "Change in Autoimmune Skin disease Intensity Score (ABSIS)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The effect of VAY736 on the IGA of a patient's disease activity will compared between baseline and Week 12. The IGA score ranges from 0 (no sign of active disease) to 4 (Severe active disease)", 
                "measure": "Change in Investigator Global Assessment (IGA)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The concentration of VAY736 will be measured in the serum. Descriptive statistics will include area under the concentration curve, half-life and time to maximum concentration.", 
                "measure": "VAY736 serum concentration", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}